Compare Abeona Therapeutics Inc (ABEO) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Lamb Weston Holdings Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Lamb Weston Holdings Inc trades at $46.46 (market cap $6.42B). The key difference: Lamb Weston Holdings Inc is far larger — about 17.2× Abeona Therapeutics Inc's market cap, and Lamb Weston Holdings Inc pays a 3.27% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | LW | |
|---|---|---|
Market Cap | $373.32M | $6.42B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $66.57 |
52-Week Low | $4.17 | $38.48 |
Enterprise Value | $228.22M | $10.39B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Lamb Weston (LW) trades at $46.51, up 1.31% on the day, with a bullish technical signal and consistent earnings beats. The company reported Q1 2026 EPS of $0.72, exceeding the $0.626 estimate, and maintains a P/E of 21.64 and P/S of 0.99. Recent news highlights its 'Focus to Win' strategy driving North America volume gains and cost savings, while activist investors like Starboard Value push for operational improvements.
The outlook is cautiously optimistic, supported by earnings momentum and strategic initiatives, but risks include a class-action lawsuit, margin pressures, and high debt levels. Analyst consensus is mixed with 35% buy ratings, reflecting balanced sentiment amid turnaround efforts and legal overhangs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
